Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE

Layla Bakaa, Jeffrey M. Pernica, Rachel J. Couban, Kelly Jo Tackett, Craig N. Burkhart, Liz Leins, Joanne Smart, Maria Teresa Garcia-Romero, Itzel Guadalupe Elizalde-Jiménez, Michael Herd, Rachel Netahe Asiniwasis, Mark Boguniewicz, Anna De Benedetto, Lina Chen, Kathy Ellison, Winfred Frazier, Matthew Greenhawt, Joey Huynh, Jennifer LeBovidge, Mary Laura LindPeter Lio, Monica O'Brien, Peck Y. Ong, Jonathan I. Silverberg, Jonathan M. Spergel, Julie Wang, Wendy Smith Begolka, Lynda Schneider, Derek K. Chu

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background: Bleach bathing is frequently recommended to treat atopic dermatitis (AD), but its efficacy and safety are uncertain. Objective: To systematically synthesize randomized controlled trials (RCTs) addressing bleach baths for AD. Methods: We searched MEDLINE, EMBASE, CENTRAL, and GREAT from inception to December 29, 2021, for RCTs assigning patients with AD to bleach vs no bleach baths. Paired reviewers independently and in duplicate screened records, extracted data, and assessed risk of bias (Cochrane version 2) and GRADE quality of evidence. We obtained unpublished data, harmonized individual patient data and did Frequentist and Bayesian random-effects meta-analyses. Results: There were 10 RCTs that enrolled 307 participants (median of mean age 7.2 years, Eczema Area Severity Index baseline mean of means 27.57 [median SD, 10.74]) for a median of 6 weeks (range, 4-10). We confirmed that other trials registered globally were terminated. Bleach baths probably improve AD severity (22% vs 32% improved Eczema Area Severity Index by 50% [ratio of means 0.78, 95% credible interval 0.59-0.99]; moderate certainty) and may slightly reduce skin Staphylococcal aureus colonization (risk ratio, 0.89 [95% confidence interval, 0.73-1.09]; low certainty). Adverse events, mostly dry skin and irritation, along with itch, patient-reported disease severity, sleep quality, quality of life, and risk of AD flares were not clearly different between groups and of low to very low certainty. Conclusion: In patients with moderate-to-severe AD, bleach baths probably improve clinician-reported severity by a relative 22%. One in 10 will likely improve severity by 50%. Changes in other patient-important outcomes are uncertain. These findings support optimal eczema care and the need for additional large clinical trials. Trial Registration: PROSPERO Identifier: CRD42021238486.

Original languageEnglish (US)
Pages (from-to)660-668.e9
JournalAnnals of Allergy, Asthma and Immunology
Issue number6
StatePublished - Jun 2022

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE'. Together they form a unique fingerprint.

Cite this